Verve Therapeutics (VERV)
(Delayed Data from NSDQ)
$6.28 USD
+0.61 (10.76%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $6.28 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VERV 6.28 +0.61(10.76%)
Will VERV be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VERV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VERV
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
VERV: What are Zacks experts saying now?
Zacks Private Portfolio Services
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls
Other News for VERV
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Verve Therapeutics Expands Board with Two New Members
Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
Verve Therapeutics appoints Nia Tatsis, Jodie Morrison to board
Cathie Wood’s top and bottom performing ARKK holdings of H1